Evidence map›Paper›PMID 36759595›Full record

ArticleSignal transduction and targeted therapy2023

Discovery of C19-9 as a novel non-RGD inhibitor of αvβ3 to overcome enzalutamide resistance in castration-resistant prostate cancer.

Xiaocong Pang, Xiaojiao Sun, Yanlun Gu, Xu He, Kan Gong, Song Song, Jixin Zhang, Jie Xia, Zhenming Liu, Yimin Cui

Open access · goldAbstract readLetter
In one paragraph

Article in Signal transduction and targeted therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Xiaocong Pang *Peking University First Hospital, Xishiku Street, Xicheng District, 100034, Beijing, China.
Xiaojiao Sun *School of Pharmaceutical Sciences, Peking University, Xueyuan Road 38, Haidian District, 100191, Beijing, China.
Yanlun Gu *Peking University First Hospital, Xishiku Street, Xicheng District, 100034, Beijing, China.
Xu HePeking University First Hospital, Xishiku Street, Xicheng District, 100034, Beijing, China.
Kan GongPeking University First Hospital, Xishiku Street, Xicheng District, 100034, Beijing, China.ORCID 0000-0001-7195-677X
Song SongSchool of Pharmaceutical Sciences, Peking University, Xueyuan Road 38, Haidian District, 100191, Beijing, China.
Jixin ZhangPeking University First Hospital, Xishiku Street, Xicheng District, 100034, Beijing, China.
Jie XiaInstitute of Materia Medica, Chinese Academy of Medical Sciences, Nanwei Road, Xicheng District, 100050, Beijing, China.
Zhenming LiuSchool of Pharmaceutical Sciences, Peking University, Xueyuan Road 38, Haidian District, 100191, Beijing, China. zmliu@bjmu.edu.cn.
Yimin CuiPeking University First Hospital, Xishiku Street, Xicheng District, 100034, Beijing, China. cui.pharm@pkufh.com.
Peking University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Prostatic Neoplasms, Castration-ResistantBenzamidesHumansMaleNitrilesPhenylthiohydantoinBenzamidesenzalutamideNitrilesPhenylthiohydantoin

Identifiers

PMID36759595
PMCPMC9911763
OpenAlexW4319663048

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.